Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by fragile skin that blisters and tears easily in response to minor trauma or friction. It is caused by mutations in the genes responsible for producing collagen, a protein that provides strength and structure to the skin. DEB primarily affects the dermis, the layer of skin beneath the epidermis, leading to various severe symptoms, including painful blisters, scarring, and contractures. The condition can vary in severity, with some individuals experiencing a more mild form while others face significant complications, including infections, nutritional issues, and an increased risk of skin cancers due to chronic damage. Treatment focuses on wound care, pain management, and complications prevention, as there is currently no cure for the condition.
Krystal Biotech, a prominent player in the biotech sphere, has shared significant updates regarding their investigational treatment, B-VEC, aimed at tackling dystrophic epidermolysis bullosa (DEB). Recently, the European Medicines Agency…